Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
about
Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosisComplementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapyComposite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates.Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazolePosaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelAntifungal pharmacokinetics and pharmacodynamicsRapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature.Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism.Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosisIn vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosisImpact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolatesIsavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.Pharmacologic and clinical evaluation of posaconazole.Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?Triazole antifungal agents in invasive fungal infections: a comparative review.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.Single-tube PCR coupled with mini-sequencing assay for the detection of cyp51A and cyp51B polymorphisms in Aspergillus fumigatus.Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxisRapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens.Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.
P2860
Q33559702-41502890-F786-4C89-A298-7829B21F9701Q33689767-6EE2EAA2-9A34-44C4-8B46-59E91C366BBBQ34290034-E28E2422-2FE9-4D64-B8A3-773FDE514F67Q34290082-C7842CEB-C4FE-46AB-B0DB-1C2579650095Q34596750-CE830B40-7A27-42CA-AC1C-14052D02BEB0Q34596761-CE7B61E4-87DC-4C8E-8157-67D10D16B74DQ34754956-81946B98-1457-4BCD-BAEC-24F45EC86427Q34977071-4BAAE750-804D-408C-8C94-CE8BBD183A92Q35065903-DD1E0F9C-FBB7-407C-B6CC-3E198EAFE6BDQ35076830-C21B485E-8852-403B-8D49-07C83700D330Q35076940-26C61CF4-7A8F-4AF2-BF7F-1DEB86BE6D4AQ35385554-5630C93A-9134-4EC4-858C-ED309BFA242CQ35663841-3CA970D6-7816-4DF8-8DD9-1E8399779DE6Q35666591-4ABC75B0-68BC-46BC-9E4A-EDA3AF4FA296Q35848799-BFB3351A-9A37-4D8E-A0C3-40A1C1E7ACDEQ36018743-C66D4872-C827-496D-BBE3-AEC62D42D292Q36171422-80A51660-2E60-4B47-941B-23235310A49AQ36505281-23AEAB0A-9672-478E-BB41-9A0DB40202EBQ36505539-919B08A1-225A-40BF-8B28-095885F96B72Q36558484-EE752C1E-21A1-4F5B-ADCF-8BD6E8B5EF84Q36757621-B8DC42B4-3AED-4FC8-9F2F-DB24FDF07FB8Q37263430-3FE69FE7-56BB-4A9C-AE2A-316F9228C22CQ37335649-6F5328D6-4B8E-4521-8DD9-836D5CC4289CQ37445943-6F7967D5-BFEB-4870-80AF-66EB99BBDD3BQ37603643-8513F0EA-85E3-433B-92C4-ED488F22B64CQ37688257-2D8A43E5-3EDC-493C-8444-51975F5FDA17Q37713035-299F05E8-02E9-46DB-80D8-AB3D39AA2F12Q37859397-A2A07F54-AA9B-4FBF-9887-9D7D558403CEQ37964703-CCA432B5-D3DB-484F-9938-E84E94077EEAQ38140015-D19664F0-92C0-43F7-B9C5-151C89AD7D3FQ38681635-28C15D04-8AD8-4697-8813-BF18448B56CBQ38919690-74585865-B00F-410F-B459-17C6AD131D6CQ38948341-7D8251EF-0A90-4B10-9AA1-A470CFB31D6CQ39003715-0BC41DB7-49C1-4A1E-80D3-2510C529A5FFQ39127825-C280C91E-5E98-435A-9859-6D2047B393B5Q39471624-41AC9AA2-C1AE-40EF-87C0-D070847D9EE4Q39901663-E961C151-BB02-4DAC-BB58-B7A5ABAC6F3BQ40045642-E295FF9A-A81C-4846-81E7-86BDD56913D7Q40083822-29F69F51-4C8D-42BD-A0F0-4438EC77F2A3Q40248126-1B5D9E1D-C6EC-47EC-87F7-927749C1FF24
P2860
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Efficacy of posaconazole again ...... mutations in the cyp51A gene.
@ast
Efficacy of posaconazole again ...... mutations in the cyp51A gene.
@en
type
label
Efficacy of posaconazole again ...... mutations in the cyp51A gene.
@ast
Efficacy of posaconazole again ...... mutations in the cyp51A gene.
@en
prefLabel
Efficacy of posaconazole again ...... mutations in the cyp51A gene.
@ast
Efficacy of posaconazole again ...... mutations in the cyp51A gene.
@en
P2093
P2860
P356
P1476
Efficacy of posaconazole again ...... h mutations in the cyp51A gene
@en
P2093
Eleftheria Mavridou
Johan W Mouton
Roger J M Brüggemann
P2860
P304
P356
10.1128/AAC.00931-09
P407
P577
2009-11-16T00:00:00Z